170 related articles for article (PubMed ID: 12684904)
1. Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study.
Imhof A; Walter RB; Schaffner A
Clin Infect Dis; 2003 Apr; 36(8):943-51. PubMed ID: 12684904
[TBL] [Abstract][Full Text] [Related]
2. Amphotericin B deoxycholate (d-AMB) use in cases with febrile neutropenia and fungal infections: lower toxicity with suitable premedication.
Oto OA; Paydas S; Disel U; Yavuz S; Seydaoglu G
Mycoses; 2007 Mar; 50(2):135-9. PubMed ID: 17305778
[TBL] [Abstract][Full Text] [Related]
3. Addition of aerosolized deoxycholate amphotericin B to systemic prophylaxis to prevent airways invasive fungal infections in allogeneic hematopoietic SCT: a single-center retrospective study.
Morello E; Pagani L; Coser P; Cavattoni I; Cortelazzo S; Casini M; Billio A; Rossi G
Bone Marrow Transplant; 2011 Jan; 46(1):132-6. PubMed ID: 20383205
[TBL] [Abstract][Full Text] [Related]
4. Implementation of clinical practice policy on the continuous intravenous administration of amphotericin B deoxycholate.
Maharom P; Thamlikitkul V
J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S118-24. PubMed ID: 17718252
[TBL] [Abstract][Full Text] [Related]
5. Continuously infused amphotericin B deoxycholate for primary treatment of invasive fungal disease in acute myeloid leukaemia.
Rothenbühler C; Held U; Manz MG; Schanz U; Gerber B
Hematol Oncol; 2018 Apr; 36(2):471-480. PubMed ID: 29431860
[TBL] [Abstract][Full Text] [Related]
6. Continuous infusion of amphotericin B: preliminary experience at Faculdade de Medicina da Fundação ABC.
Uehara RP; Sá VH; Koshimura ET; Prudente FV; Tucunduva LT; Gonçalves MS; Samano ES; del Giglio A
Sao Paulo Med J; 2005 Sep; 123(5):219-22. PubMed ID: 16358096
[TBL] [Abstract][Full Text] [Related]
7. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial.
Cordonnier C; Pautas C; Maury S; Vekhoff A; Farhat H; Suarez F; Dhédin N; Isnard F; Ades L; Kuhnowski F; Foulet F; Kuentz M; Maison P; Bretagne S; Schwarzinger M
Clin Infect Dis; 2009 Apr; 48(8):1042-51. PubMed ID: 19281327
[TBL] [Abstract][Full Text] [Related]
8. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study.
Lowry CM; Marty FM; Vargas SO; Lee JT; Fiumara K; Deykin A; Baden LR
Transpl Infect Dis; 2007 Jun; 9(2):121-5. PubMed ID: 17461997
[TBL] [Abstract][Full Text] [Related]
9. continuous versus conventional infusion of amphotericin B deoxycholate: a meta-analysis.
Falagas ME; Karageorgopoulos DE; Tansarli GS
PLoS One; 2013; 8(10):e77075. PubMed ID: 24204739
[TBL] [Abstract][Full Text] [Related]
10. Amphotericin B in poly(lactic-co-glycolic acid) (PLGA) and dimercaptosuccinic acid (DMSA) nanoparticles against paracoccidioidomycosis.
Amaral AC; Bocca AL; Ribeiro AM; Nunes J; Peixoto DL; Simioni AR; Primo FL; Lacava ZG; Bentes R; Titze-de-Almeida R; Tedesco AC; Morais PC; Felipe MS
J Antimicrob Chemother; 2009 Mar; 63(3):526-33. PubMed ID: 19151037
[TBL] [Abstract][Full Text] [Related]
11. Amphotericin B deoxycholate administered by continuous infusion: does the dosage make a difference?
Hiemenz JW
Clin Infect Dis; 2003 Apr; 36(8):952-3. PubMed ID: 12684905
[No Abstract] [Full Text] [Related]
12. Continuous and 4 h infusion of amphotericin B: a comparative study involving high-risk haematology patients.
Peleg AY; Woods ML
J Antimicrob Chemother; 2004 Oct; 54(4):803-8. PubMed ID: 15308606
[TBL] [Abstract][Full Text] [Related]
13. Amphotericin B deoxycholate: no significant advantage of a 24 h over a 6 h infusion schedule.
Altmannsberger P; Holler E; Andreesen R; Krause SW
J Antimicrob Chemother; 2007 Jul; 60(1):180-2. PubMed ID: 17537868
[No Abstract] [Full Text] [Related]
14. [Amphotericin B deoxycholate prescription and adverse events in a Chilean university hospital].
Quinteros A R; Fica C A; Abusada A N; Muñoz C L; Novoa M C; Gallardo A C
Rev Chilena Infectol; 2010 Feb; 27(1):25-33. PubMed ID: 20140311
[TBL] [Abstract][Full Text] [Related]
15. Comparative pharmacokinetics and safety of a novel lyophilized amphotericin B lecithin-based oil-water microemulsion and amphotericin B deoxycholate in animal models.
Brime B; Frutos P; Bringas P; Nieto A; Ballesteros MP; Frutos G
J Antimicrob Chemother; 2003 Jul; 52(1):103-9. PubMed ID: 12805269
[TBL] [Abstract][Full Text] [Related]
16. Empirical antifungal therapy in treating febrile neutropenic patients.
Wingard JR
Clin Infect Dis; 2004 Jul; 39 Suppl 1():S38-43. PubMed ID: 15250019
[TBL] [Abstract][Full Text] [Related]
17. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study.
Cordonnier C; Mohty M; Faucher C; Pautas C; Robin M; Vey N; Monchecourt F; Mahi L; Ribaud P
Int J Antimicrob Agents; 2008 Feb; 31(2):135-41. PubMed ID: 18162375
[TBL] [Abstract][Full Text] [Related]
18. In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against Candida species in the presence of human serum albumin.
Lewis RE; Wiederhold NP; Prince RA; Kontoyiannis DP
J Antimicrob Chemother; 2006 Feb; 57(2):288-93. PubMed ID: 16387749
[TBL] [Abstract][Full Text] [Related]
19. Retrospective study of the renal effects of amphotericin B lipid complex when used at higher-than-recommended dosages and longer durations compared with lower dosages and shorter durations in patients with systemic fungal infections.
Hooshmand-Rad R; Reed MD; Chu A; Gotz V; Morris JA; Weinberg J; Dominguez EA
Clin Ther; 2004 Oct; 26(10):1652-62. PubMed ID: 15598482
[TBL] [Abstract][Full Text] [Related]
20. Continuous infusion of amphotericin B deoxycholate: a cost-effective gold standard for therapy of invasive fungal infections?
Schneemann M; Bachli EB
Clin Infect Dis; 2004 Jan; 38(2):303-4; author reply 306-7. PubMed ID: 14699468
[No Abstract] [Full Text] [Related]
[Next] [New Search]
